Upon thawing, myrCell Ventricular Cardiomyocytes rapidly acquire a robust ventricular phenotype and express key cardiac markers such as cTnT, 伪-actinin, NCX1, MYH7, and MLC2v. Derived from iPSCs and driven by precisely optimised directed differentiation protocols, these cells form functional, electrically coupled monolayers and develop spontaneous, synchronised contractions within 7 days post-thaw.

Whether used in 2D or 3D culture systems, their organised sarcomeres, synchronised beating, and metabolic maturity deliver a fully human-relevant cardiac model鈥攅ffectively bridging the gap between simple in vitro assays and complex tissue physiology.

myrCell Atrial Cardiomyocytes exhibit a robust atrial phenotype, expressing both pan-cardiac markers (cTnT, 伪-actinin) and distinguishing chamber-specific markers including NPPA, MYH6, and KCNA5. Generated using traditional directed differentiation protocols and delivered cryopreserved, the cells form electrically coupled monolayers and develop spontaneous, synchronised contractions within days post-thaw.

When paired with myrCell Ventricular Cardiomyocytes, they provide a genetically matched toolkit for target validation, atrial-selective cardiac safety pharmacology, and modelling disease such as atrial fibrillation.

Both Atrial and Ventricular Cardiomyocytes establish electrically coupled 2D monolayers and begin spontaneous, synchronised contractions within days post-thaw.

The atrial and ventricular cardiomyocyte populations display different electrophysiology patterns, including distinct ion channel profiles, with the atrial cardiomyocytes displaying a significantly shorter action potential duration compared to the ventricular cells. Both cell populations remain functionally active for approximately 50 days in 2D culture.

Beyond standard 2D monocultures, myrCell Ventricular Cardiomyocytes have been optimised for the generation of 3D engineered heart muscle (EHM). When combined with cardiac fibroblasts in a collagen-based hydrogel, they form highly functional tissues that develop physiologically relevant contractile force and robust tissue elasticity.

By exhibiting mature force-frequency responses within this 3D architecture, the cells offer a highly predictive, human-relevant model for translational cardiovascular research and drug discovery workflows.

Wild-type myrCell Ventricular Cardiomyocytes serve as the ideal isogenic control for CRISPR-engineered disease models, such as the genetically matched Titin (TTN) A-band mutation Ventricular Cardiomyocytes product for modelling dilated cardiomyopathy (DCM).

The use of a genetically-matched control enables the comparison between healthy functionality and disease-associated mutations while minimising genetic background variability, providing a tool for target validation and the testing of novel therapeutics.

For drug discovery programs and mechanistic studies requiring real-time, quantitative structural readouts alongside contractile function, myrCell SarcPaint Ventricular Cardiomyocytes provide a robust tool for live-cell imaging.

These cells exhibit the same gene expression and functional profile as wild-type ventricular cardiomyocytes, whilst carrying a genetically encoded ACTN2-Citrine reporter (SarcPaint). This reporter provides fluorescently tagged sarcomeric 伪-actinin for continuous structural assessment without the need for fixation or immunostaining. Consequently, sarcomere structure and organisation can be readily quantified using standard image analysis platforms or AI-assisted algorithms, enabling automated, high-content screening in live cardiomyocytes.